Search
Sulfamoxole
go.drugbank.com/drugs/DB08798ExperimentalSulfamoxole is an antibacterial in the sulfonamide class.
Synonyms: 2-(p-Aminobenzenesulfonamido)-4,5-dimethyloxazole, 2-(p-Aminobenzolsulfonamido)-4,5-dimethyloxazolCategories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 Enzyme InhibitorsTofisopam
go.drugbank.com/drugs/DB08811InvestigationalTofisopam (marketed under brand names Emandaxin and Grandaxin) is a 2,3-benzodiazepine drug which is a benzodiazepine derivative. In contrast to classical 1,4-benzodiazepines, the compound does not bind to the benzodiazepine binding site...
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsVismodegib
go.drugbank.com/drugs/DB08828ApprovedInvestigationalVismodegib is an orally active small molecule that inhibits the hedgehog signaling pathway by binding to and inhibiting the transmembrane protein smoothened homologue (SMO). It was discovered by high-throughput screening of a library of ...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesBoceprevir
go.drugbank.com/drugs/DB08873ApprovedWithdrawnBoceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesVemurafenib
go.drugbank.com/drugs/DB08881ApprovedInvestigationalVemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxiko...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesCarfilzomib
go.drugbank.com/drugs/DB08889ApprovedInvestigationalCarfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treat...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesPerospirone
go.drugbank.com/drugs/DB08922InvestigationalPerospirone is an atypical or second-generation antipsychotic of the azapirone family that antagonizes serotonin 5HT2A receptors and dopamine D2 receptors. It also displays affinity towards 5HT1A receptors as a partial agonist. Dainippon...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesMacitentan
go.drugbank.com/drugs/DB08932ApprovedInvestigationalMacitentan is a dual endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension (PAH). It was first approved by the FDA in 2013. Macitentan differs from its predecessor bosentan in part due to its lower risk ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 SubstratesAzosemide
go.drugbank.com/drugs/DB08961InvestigationalAzosemide is a loop diuretic used to treat hypertension, edema, and ascites.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesGlibornuride
go.drugbank.com/drugs/DB08962ApprovedWithdrawnGlibornuride is a sulfonylurea-type anti-diabetic drug.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Substrates